But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.